Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
10732718
Knihovny.cz E-zdroje
- MeSH
- aktivní imunoterapie * MeSH
- buňky NK imunologie MeSH
- CD4-pozitivní T-lymfocyty imunologie MeSH
- cytotoxické T-lymfocyty imunologie MeSH
- cytotoxické testy imunologické MeSH
- experimentální sarkom metabolismus patologie MeSH
- genetická terapie * MeSH
- interleukin-2 genetika MeSH
- karcinom imunologie patologie chirurgie terapie MeSH
- kombinovaná terapie MeSH
- komplementární DNA genetika MeSH
- lokální recidiva nádoru prevence a kontrola terapie MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- nádorové buňky kultivované imunologie účinky záření transplantace MeSH
- progrese nemoci MeSH
- protinádorové vakcíny terapeutické užití MeSH
- rekombinantní fúzní proteiny fyziologie MeSH
- reziduální nádor MeSH
- slezina imunologie MeSH
- transfekce MeSH
- transplantace nádorů MeSH
- vakcinace * MeSH
- zkřížené reakce MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- interleukin-2 MeSH
- komplementární DNA MeSH
- protinádorové vakcíny MeSH
- rekombinantní fúzní proteiny MeSH
Experiments were designed to characterize cytolytic effector cells from mice with SMRTD treated with IL-2 gene therapy. Mice were inoculated with syngeneic murine MK16 carcinoma cells. When the tumours reached 8-12 mm in diameter, they were excised and the operated mice were randomized into two groups. The first group without any further treatment was designated as operated-only; the second group, vaccinated 3 days after the operation with IL-2-producing tumour vaccine, is referred to as operated-vaccinated. Tumour recurrence rate in the operated-only mice was 90 percent; in the operated-vaccinated group the recurrence rate was 38.5 percent (progressors). The remaining 61.5 percent of mice were permanently protected (regressors). On day 53, the tumour progressors, regressors and healthy controls were sacrificed, and their spleen cells were used for 51Cr microcytotoxicity assay. Splenocytes from any group of mice were not cytolytic when allowed to react with MK16, YAC-1 (NK sensitive) and C1498 (NK resistant) targets. However, when grown for 3 days in IL-2-containing medium, the splenocytes from all groups of mice could develop cytolytic activity. The cytolytic activity of splenocytes from tumour progressors and regressors was substantially lower then that of splenocytes from healthy controls. In addition, significantly lower cytolytic activity was observed with IL-2-activated splenocytes from tumour progressors as compared to that of tumour regressors. Depletion of NK1.1+ cells or CD4+ plus CD8+ cells prevented the induction of significant IL-2-stimulated cytotoxicity directed against MK16 and C1498 targets in spleen cell cultures from tumour progressors, regressors, and healthy control mice, indicating that both, NK1.1+ and CD4+ plus CD8+, cells participate in the antitumour effect of IL-2 gene therapy. This was further supported by the finding that after depletion of CD4+ plus CD8+ cells, a residual cytolytic activity directed exclusively against NK-sensitive YAC-1 cells was observed.